Cardiovascular Research Advance Access [Accepted Manuscript] published online on June 4, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp183
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A potential link between PPAR signaling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (ARVC)
1 Université Paris Descartes, CNRS UPR9078, Faculté Necker, Assistance Publique-Hôpitaux de Paris, Paris
2 Services d'Explorations CardioRespiratoires, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre
3 Centre de Recherche Clinique, Hôpital de Meaux
4 Université Pierre et Marie Curie-Paris 6, Inserm U621 and Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris
5 INSERM U974, UPMC Univ Paris 06, Paris
Address for correspondence: Catherine Coirault, INSERM U974, GH Pitié-Salpétrière, 47 Bd de l'Hôpital, 75651 PARIS Cedex 13. Tel: 331 42 16 57 55, Fax: 331 42 16 57 00, E-mail: c.coirault{at}institut-myologie.org
Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by major fibro-fatty replacement of the right ventricle (RV). We hypothesized that changes in peroxisome proliferators-activated receptor (PPAR) signaling contributed to myocardium fatty accumulation and contractile dysfunction in ARVC.
Methods: Real-time quantitative RT-PCR and Western blotting were used to assess cardiac expression of PPAR
and
and two of their downstream target genes – medium-chain acyl-CoA dehydrogenase (MCAD) and phosphoenolpyruvate carboxykinase (PEPCK) – in both right and left ventricles (RV, LV) from 5 controls and 5 ARVC patients. In vitro motility assays were used to analyze functional properties of myosin.
Results: In the RV, sliding velocity was nearly twofold lower in ARVC than in controls, whereas a 10 % reduction in velocity values was noted between ARVC and non-failing myocardium in the LV. In controls, PPAR
and MCAD mRNA and protein levels were higher in the RV compared to the LV. In ARVC, the expression of PPAR
and MCAD mRNA and/or proteins was decreased in both RV and LV. RV from ARVC was also characterized by a dramatic activation of the PPAR
pathway, as attested by the increase in PPAR
mRNA and protein (+500% and +270%, respectively, each p<0.001) and by the induction of PEPCK gene. In contrast, the LV of ARVC heart exhibited no changes in the expression of the PPAR
regulatory pathway compared to control.
Conclusion: ARVC is associated with major disturbances in the PPAR
and PPAR
signaling pathway in the RV that may contribute to intracellular lipid overload and severe myosin dysfunction.
KEYWORDS cardiomyopathy; contractile apparatus; heart failure; lipid signaling
Time for primary review: 50 Days